Serum level of pepsinogen significantly associated with gastric distress induced by amino-bisphosphonates

Osteoporosis International

Volumn 22, Issue 6, 2011, Pages 1717-1723

  Shiraki, M ^a   Yamazaki, Y ^a   Kuroda, T ^b   Tanaka, S ^c   Miyata, K ^d  

^a Research Institute and Practice for Involutional Diseases   (Japan)

^b Nishiyama Kogyo Ochanomizu Building 5F   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d Aizawa Hospital   (Japan)

Author keywords

Amino bisphosphonates; Gastrointestinal adverse event; Osteoporosis; Pepsinogen

Indexed keywords

ALENDRONIC ACID; PEPSINOGEN I; PEPSINOGEN II; RISEDRONIC ACID;

ABDOMINAL FULLNESS; AGED; ANOREXIA; CONFERENCE PAPER; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DUODENUM ULCER; ENDOSCOPY; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOPOROSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SIDE EFFECT; STOMACH IRRITATION; STOMACH LESION; STOMACH MUCOSA LESION; STOMACH PAIN; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CHEMISTRY, PHARMACEUTICAL; DIPHOSPHONATES; FEMALE; GASTROINTESTINAL DISEASES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPSINOGEN A; PEPSINOGEN C; PEPSINOGENS;

EID: 79959945882     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1374-3     Document Type: Conference Paper

References (27)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541 (Pubitemid 26411651)
2. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352 (Pubitemid 29483192)
3. DeGroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. New Engl J Med 335:1016-1021 (Pubitemid 26338731)
4. Kane S, Borison NN, Brixner D (2004) Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: a retrospective cohort study. Am J Manage Care 10:S216-S226 (Pubitemid 39100333)
5. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914-921 (Pubitemid 43781506)
6. Lichtenberger L, Romero JJ, Gibson GW, Blank MA (2000) Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45:1792-1801
7. Hills BA, Butler BD, Lichtenberger LM (1983) The gastric mucosal barrier; the hydrophobic lining to the lumen of the stomach. Am J Physiol 244:G561-G568 (Pubitemid 13101277)
8. Lichtenberger LM (1995) The hydrophobic barrier properties of gastrointestinal mucus. Ann Rev Physiol 57:565-583
9. Lichternberger LM, Graziani LA, Dial EJ, Butler BD, Holls BA (1983) Role of surface-active phospholipids in gastric cytoprotection. Science 219:1327-1329 (Pubitemid 13109164)
10. Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM (1999) Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 94:1818-1822 (Pubitemid 29315892)
11. Derakhshan MH, El-Omar E, Oien K, Gillen D, Fyfe V, Crabtree JE, McColl KEL (2006) Gsatric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobactor pylori. J Clin Pathol 59:1293-1299 (Pubitemid 46048335)
12. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Ohashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Osteoporosis diagnostic criteria review committee: Japanese Society for Bone and mineral research. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
13. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D, for the Fracture Intervention Trial Research Group (2000) Upper Gastrointestinal tract safety profile of alendronate. Arch Intern Med 160:517-525
14. Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, Robert A, Zippel H, Adami S, Ernst TF, Stevens KP (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77:262-270 (Pubitemid 34177602)
15. Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yetes J, DePapp AE, Palmesano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044-1052
16. Tremaine WJ, Khosla S (2002) Bisphosphonates and upper gastrointestinal tract: skeletal gain without visceral pain? Mayo Clin Proc 77:1029-1030
17. Samioff IM, Taggart RT (1987) Pepsinogens, pepsins, and peptic ulcer. Clin Invest Med 10:215-221 (Pubitemid 17113564)
18. Kemppainen H, Raiha I, Sourander L (1997) Serum pepsinogen I and gastrin in peptic ulcer patients using nonsteroidal antiinflammatory drugs. Hepatogastroenterology 44:1143-1146 (Pubitemid 27326173)
19. Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, Miyazaki T, Miki K, Graham DY (1992) Relationship of Helicobactor pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 102:760-766
20. Kumagai T, Malaty HM, Graham DY, Hosogaya S, Misawa K, Furihata K, Ota H, Sei C, Tanaka E, Akamatsu T, Shimizu T, Kiyosawa K, Katsuyama T (1998) Acquisition versus loss of Helicobactor pylori infection in Japan: results from 8-year birth cohort study. J Infect Dis 178:717-721 (Pubitemid 28397219)
21. Miki K, Urita Y (2007) Using serum pepsinogens wisely in a clinical practice. J Dig Dis 8:8-14 (Pubitemid 46189204)
22. Roughead EE, McGeechan K, Sayer GP (2004) Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 57:813-816 (Pubitemid 38748050)
23. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947-2953 (Pubitemid 46021498)
24. Vestaagard P, Rejmark L, Mosekilde L (2006) Proton pump inhibitors, histamin H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76-83 (Pubitemid 44306164)
25. De Vries F, Cooper AL, Cockle SM, van Staa T-P, Cooper C (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20:1989-1998
26. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG (1995) Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298
27. Lahner E, Annibale B, Fave GD (2009) Systemic review: impared drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 29:1219-1229